TrialThe Lancet. Neurology2024

Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.

Mukul Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.